- $3.36bn
- $3.30bn
- $476.54m
- 91
- 20
- 96
- 78
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 138 | 204 | 274 | 408 | 477 |
Cost of Revenue | |||||
Gross Profit | 74.1 | 116 | 162 | 239 | 285 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 166 | 247 | 345 | 502 | 516 |
Operating Profit | -28.2 | -42.6 | -71.4 | -94 | -39.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -27.1 | -40.7 | -74 | -97.8 | -41.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.7 | -41.3 | -50.1 | -102 | -43.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -27.6 | -40.5 | -49.4 | -103 | -42.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -27.6 | -40.5 | -49.4 | -103 | -42.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.308 | -0.462 | -0.375 | -0.815 | -0.341 |
Dividends per Share |